OnKure (OKUR) ADAR1 group reports 6.0% stake

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. Schedule 13G/A reports that ADAR1-related reporting persons and Daniel Schneeberger beneficially own 2,434,941 shares of Class A Common Stock, representing 6.0% of the class, based on 40,395,480 shares outstanding as of March 31, 2026.

The filing states the 2,434,941 figure reflects aggregated holdings across ADAR1 Partners, LP; Spearhead Insurance Solutions IDF, LLC; and other separately managed accounts, and that Mr. Schneeberger may be deemed an indirect beneficial owner as manager and control person. The share counts and the March 31, 2026 time anchor are cited from the filing and the issuer's Form 10-Q reported on May 5, 2026.

Insights

Corporate Governance Specialist

ADAR1 group reports a 6.0% indirect stake in OnKure as of March 31, 2026.

ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC and Daniel Schneeberger are listed as reporting persons, with aggregated shared voting and dispositive power over 2,434,941 shares. The filing ties the share counts to the issuer's stated outstanding shares of 40,395,480 as of March 31, 2026.

Classification notes: the filing describes indirect beneficial ownership through advisory and GP relationships and identifies Mr. Schneeberger as a control person in respect of those holdings. Subsequent disclosures or amendments would be needed to show any change in ownership or voting arrangements.

Key Figures

Shares beneficially owned: 2,434,941 shares Percent of class: 6.0% Shares outstanding: 40,395,480 shares +3 more

6 metrics

Shares beneficially owned 2,434,941 shares Aggregate holdings reported by ADAR1-related filers and Daniel Schneeberger as of March 31, 2026

Percent of class 6.0% Percentage of Class A Common Stock based on shares outstanding as of March 31, 2026

Shares outstanding 40,395,480 shares OnKure shares outstanding as of March 31, 2026, cited from the issuer's Form 10-Q

ADAR1 Partners holdings (subset) 2,038,429 shares Shares held by ADAR1 Partners, LP as of March 31, 2026

Spearhead Insurance holdings (subset) 295,020 shares Shares held by Spearhead Insurance Solutions IDF, LLC as of March 31, 2026

Other separately managed accounts (subset) 101,492 shares Shares held by other separately managed accounts as of March 31, 2026

Key Terms

Schedule 13G/A, beneficially own, shared dispositive power, control person

4 terms

Schedule 13G/A regulatory

"OnKure Therapeutics, Inc. — Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially own regulatory

"may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

shared dispositive power financial

"Shared Dispositive Power 2,434,941.00"

control person regulatory

"Mr. Schneeberger is filing this as a control person in respect of shares beneficially owned"

A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does ADAR1 hold in OnKure (OKUR)?

ADAR1-related filers and Daniel Schneeberger report beneficial ownership of 2,434,941 shares, equal to 6.0% of Class A common stock, based on 40,395,480 shares outstanding as of March 31, 2026.

Who are the reporting persons on the Schedule 13G/A for OKUR?

The filing is made on behalf of ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger, with a shared principal business address in Austin, Texas.

Are the ADAR1 holdings direct or indirect in the OKUR filing?

The filing states the holdings are indirect beneficial ownership through ADAR1 Partners, LP, advisory relationships and separately managed accounts, and attributes indirect ownership to ADAR1 entities and Mr. Schneeberger.

What is the time anchor and source for the outstanding share count cited?

The outstanding share base of 40,395,480 shares is reported as of March 31, 2026 and is cited from the issuer's Form 10-Q filed on May 5, 2026 in the Schedule 13G/A.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 08:20 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

OnKure Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

68277Q105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 68277Q105

1

Names of Reporting Persons

ADAR1 Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,434,941.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,434,941.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,434,941.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Includes (i) 2,038,429 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 295,020 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 101,492 shares of Common Stock held by other separately managed accounts as of March 31, 2026. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 40,395,480 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 5, 2026.

SCHEDULE 13G

CUSIP Number(s): 68277Q105

1

Names of Reporting Persons

ADAR1 Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,038,429.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,038,429.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,038,429.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Includes 2,038,429 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP as of March 31, 2026. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 40,395,480 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 5, 2026.

SCHEDULE 13G

CUSIP Number(s): 68277Q105

1

Names of Reporting Persons

Daniel Schneeberger

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,434,941.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,434,941.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,434,941.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes (i) 2,038,429 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 295,020 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 101,492 shares of Common Stock held by other separately managed accounts as of March 31, 2026. As the manager of ADAR1 Capital Management, LLC, and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 40,395,480 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 5, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OnKure Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6707 Winchester Circle, Suite 400 Boulder, CO 80301
Item 2.
(a)	Name of person filing: This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and (iii) Daniel Schneeberger ("Mr. Schneeberger").
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)	Citizenship: (i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; and (iii) Mr. Schneeberger is a citizen of Switzerland.
(d)	Title of class of securities: Class A Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 68277Q105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)	Percent of class: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ADAR1 Capital Management, LLC

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, Manager
Date:	05/15/2026

ADAR1 Capital Management GP, LLC

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, Manager
Date:	05/15/2026

Daniel Schneeberger

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, in his individual capacity
Date:	05/15/2026